Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$154.76 USD
-3.98 (-2.50%)
Updated May 10, 2024 04:00 PM ET
After-Market: $154.58 -0.18 (-0.12%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Krystal Biotech, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 51 | 0 | 0 | 0 | 0 |
Cost Of Goods | 3 | 0 | 0 | 0 | 0 |
Gross Profit | 48 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 157 | 145 | 68 | 33 | 22 |
Income After Depreciation & Amortization | -110 | -145 | -68 | -33 | -22 |
Non-Operating Income | 123 | 5 | 0 | 1 | 3 |
Interest Expense | 0 | 0 | 1 | 0 | 0 |
Pretax Income | 13 | -140 | -70 | -32 | -19 |
Income Taxes | 2 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 11 | -140 | -70 | -32 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 11 | -140 | -70 | -32 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -106 | -141 | -66 | -31 | -21 |
Depreciation & Amortization (Cash Flow) | 4 | 4 | 3 | 2 | 1 |
Income After Depreciation & Amortization | -110 | -145 | -68 | -33 | -22 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 27.75 | 25.49 | 22.20 | 18.79 | 15.90 |
Diluted EPS Before Non-Recurring Items | -2.76 | -4.51 | -3.13 | -1.71 | -1.20 |
Diluted Net EPS (GAAP) | 0.39 | -5.49 | -3.13 | -1.71 | -1.20 |
Fiscal Year end for Krystal Biotech, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 42.14 | 8.56 | 0.00 | 0.00 |
Cost Of Goods | NA | 2.87 | 0.22 | 0.00 | 0.00 |
Gross Profit | NA | 39.27 | 8.33 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 36.14 | 34.33 | 38.04 | 48.83 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.13 | -26.00 | -38.04 | -48.83 |
Non-Operating Income | NA | 7.52 | 106.74 | 4.84 | 3.53 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 10.66 | 80.75 | -33.21 | -45.30 |
Income Taxes | NA | 1.97 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 8.69 | 80.75 | -33.21 | -45.30 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 8.69 | 80.75 | -33.21 | -45.30 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 28.82 | 28.89 | 26.66 | 25.71 |
Diluted EPS Before Non-Recurring Items | NA | 0.30 | -0.67 | -1.25 | -1.76 |
Diluted Net EPS (GAAP) | NA | 0.61 | 2.79 | -1.25 | -1.76 |